



Data rates may apply.

Tips to help manage your treatment experience

Talk to your doctor about what steps are right for you.

Daily, at-home care options to discuss with your care team



Limit direct exposure to sunlight

Wear protective clothing and sunscreen with SPF ≥30



Mild, ceramide-based moisturizer (such as La Roche-Posay Lipikar or CeraVe*†)

Use on your face and body (except scalp) at least once a day

*Talk to your doctor about what is right for you.

†All trademarks are property of their respective owners.



Antiseptic cleanser (such as chlorhexidine 4%)

Use to wash your fingernails and toenails once a day

Other medicines



- **Oral antibiotics** (for the first 3 months of treatment) followed by an **antibiotic lotion** for your scalp (for the next 9 months) may be prescribed to reduce risk of skin-related side effects
- **Medicine to lower your risk of blood clots** will be prescribed for the first 4 months of treatment

Make sure to tell your doctor about any other medicines you are taking. Consider using a pill box to help you organize your medicines.

More tips to help throughout treatment



- Consider bathing/showering with warm or cool water (not hot water)
- Use mild soaps and shampoos for sensitive skin



- Use laundry detergents made for sensitive skin and without perfumes
- Wear soft, loose-fitting clothing
- Wear gloves during activities that could cause nail infection (for example, cleaning)



- Eat a balanced diet
- Talk to your doctor about activities that feel right for you
- Seek out support from your family, friends, care team, and/or support groups

Once you and your doctor have decided that a RYBREVANT FASPRO™-based treatment is right for you, sign up for:

RYBREVANT withMe

Personalized 1-on-1 support

You have access to free, dedicated support. Your Care Navigator is here to help guide you to support solutions throughout your treatment journey.

Visit RYBREVANTwithMe.com/signup OR

Call 833-JNJ-wMe1 (833-565-9631),

Monday through Friday, 8:00 AM–8:00 PM ET.

Sign up now:



Data rates may apply.

The support and resources provided by RYBREVANT withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

Please see attached Important Safety Information.

Please read full Prescribing Information for **RYBREVANT FASPRO™**, **RYBREVANT®**, and **LAZCLUZE®**.

IMPORTANT SAFETY INFORMATION

What are RYBREVANT FASPRO™ (amivantamab and hyaluronidase-Ipuj) and RYBREVANT® (amivantamab-vmjw)?

RYBREVANT FASPRO™ and RYBREVANT® are prescription medicines used to treat adults with non–small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and has certain abnormal epidermal growth factor receptor (EGFR) gene(s):

- in combination with LAZCLUZE® (lazertinib), a prescription medicine, as a first-line treatment for NSCLC
- in combination with carboplatin and pemetrexed for NSCLC in people whose disease has worsened on or after treatment with an EGFR tyrosine kinase inhibitor (TKI)
- in combination with carboplatin and pemetrexed as a first-line treatment for NSCLC
- alone for the treatment of NSCLC in people whose disease has worsened on or after platinum-based chemotherapy.

Your healthcare provider will perform a test to make sure that RYBREVANT FASPRO™ or RYBREVANT® is right for you.

It is not known if RYBREVANT FASPRO™, RYBREVANT®, or LAZCLUZE® are safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not take RYBREVANT FASPRO™ if you are allergic to hyaluronidase or any of the ingredients in RYBREVANT FASPRO™.

Before you receive RYBREVANT FASPRO™, RYBREVANT® or LAZCLUZE®, tell your healthcare provider (HCP) about all of your medical conditions, including if you:

- have a history of lung or breathing problems, other than cancer.
- are pregnant or plan to become pregnant. RYBREVANT FASPRO™, RYBREVANT®, and LAZCLUZE® can harm your unborn baby.

Females who are able to become pregnant:

- o Your HCP should do a pregnancy test before you start treatment with RYBREVANT FASPRO™, RYBREVANT®, or LAZCLUZE®.
- o If you are taking RYBREVANT FASPRO™ or RYBREVANT®, use effective birth control (contraception) during treatment and for 3 months after your last dose. If you are taking LAZCLUZE®, use effective birth control (contraception) during treatment and for 3 weeks after your last dose.
- o Tell your HCP right away if you become pregnant or think you might be pregnant during treatment with RYBREVANT FASPRO™, RYBREVANT®, or LAZCLUZE®.

Males who have female partners who are able to become pregnant:

- o You should use effective birth control during treatment and for 3 weeks after your last dose of LAZCLUZE®.
- are breastfeeding or plan to breastfeed. It is not known if RYBREVANT FASPRO™, RYBREVANT®, or LAZCLUZE® pass into your breast milk. Do not breastfeed during treatment and for 3 months after your last dose of RYBREVANT FASPRO™ or RYBREVANT®. Do not breastfeed during treatment and for 3 weeks after your last dose of LAZCLUZE®.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. LAZCLUZE® may affect the way other medicines work, and other medicines may affect how LAZCLUZE® works. You should not start or stop any medicine before you talk with your HCP that prescribed LAZCLUZE®.

What should I avoid while receiving RYBREVANT FASPRO™, RYBREVANT®, and/or LAZCLUZE®?

RYBREVANT FASPRO™, RYBREVANT®, and LAZCLUZE® can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment. Wear protective clothing and use broad-spectrum sunscreen during treatment.

What are the possible side effects of RYBREVANT FASPRO™, RYBREVANT®, or LAZCLUZE®?

RYBREVANT FASPRO™, RYBREVANT®, and LAZCLUZE® may cause serious side effects, including:

- **allergic and injection-related reactions.** Allergic and injection-related reactions are common with RYBREVANT FASPRO™ and can be severe or serious. Tell your HCP right away if you get any of the following symptoms during or after your injection: shortness of breath, fever, chills, flushing, chest discomfort, dizziness or lightheadedness, or vomiting.
- **infusion-related reactions.** Infusion-related reactions are common with RYBREVANT® but can be severe or serious and can include life-threatening (anaphylaxis) allergic reaction. Tell your HCP right away if you get any of the following symptoms during your infusion of RYBREVANT®: shortness of breath, difficulty breathing, or wheezing, chest discomfort, swelling of your eyes, lips, or tongue, fever, chills, numbness of your tongue, lips, cheeks, or gums, flushing, skin rash, hives, or itching, nausea or vomiting, stomach cramps, lightheadedness, dizziness, or fainting, or headache.
- **lung problems.** RYBREVANT FASPRO™, RYBREVANT®, or LAZCLUZE® can cause lung problems that can lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your HCP right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
- **blood clot problems.** RYBREVANT FASPRO™ or RYBREVANT®, when given in combination with LAZCLUZE®, can cause blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that can lead to death. Your HCP may start you on medicine to prevent blood clots for the first 4 months of treatment. Tell your HCP right away if you get any signs and symptoms of blood clots, including swelling, pain or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.
- **skin problems.** RYBREVANT FASPRO™, RYBREVANT®, or LAZCLUZE® can cause severe rash, including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. Your HCP may start you on an antibiotic for the first 3 months of treatment followed by an antibiotic lotion for your scalp for the next 9 months. During treatment, you should apply a non-comedogenic (does not clog pores) skin moisturizer (ceramide-based or other types of moisturizers that provide long lasting skin hydration and does not include drying ingredients) on your face and whole body (except scalp) and wash your hands and feet every day with 4% chlorhexidine solution. Tell your HCP right away if you get any skin reactions. Your HCP may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment.



IMPORTANT SAFETY INFORMATION (cont'd)

- eye problems.** RYBREVANT FASPRO™, RYBREVANT®, and LAZCLUZE® can cause eye problems. Tell your HCP right away if you get symptoms of eye problems including eye pain, inflammation of eyelids, dry eyes, eye redness, blurred vision, changes in vision, itchy eyes, excessive tearing, and sensitivity to light. Your HCP may send you to see an eye specialist (ophthalmologist) if you get new or worsening eye problems during treatment with RYBREVANT FASPRO™, RYBREVANT®, or LAZCLUZE®. You should not use contact lenses until your eye symptoms are checked by an HCP.

The most common side effects of RYBREVANT FASPRO™ in combination with LAZCLUZE® include: rash, infected skin around the nail, muscle and joint pain, feeling very tired, sores in the mouth, swelling of hands, ankles, feet, face, or all of your body, nausea, diarrhea, vomiting, constipation, decreased appetite, headache, and changes in certain blood tests.

The most common side effects seen with intravenous (IV) RYBREVANT®, which may be experienced with RYBREVANT FASPRO™, are listed below.

- RYBREVANT® in combination with LAZCLUZE®:** rash, infected skin around the nail, infusion-related reaction, muscle and joint pain, sores in the mouth, swelling of hands, ankles, feet, face, or all of your body, unusual feeling in the skin (such as tingling or a crawling feeling), feeling very tired, diarrhea, constipation, COVID-19, bleeding, dry skin, decreased appetite, itchy skin, nausea, and changes in certain blood tests.
- RYBREVANT® in combination with carboplatin and pemetrexed:** rash, infected skin around the nail, infusion-related reaction, feeling very tired, nausea, sores in the mouth, constipation, swelling of hands, ankles, feet, face, or all of your body, decreased appetite, muscle and joint pain, vomiting, COVID-19, and changes in certain blood tests.
- RYBREVANT® given alone:** rash, infusion-related reaction, infected skin around the nail, muscle and joint pain, shortness of breath, nausea, swelling of hands, ankles, feet, face, or all of your body, cough, feeling very tired, sores in the mouth, constipation, vomiting, and changes in certain blood tests.

LAZCLUZE® may cause fertility problems in males and females, which may affect your ability to have children. Talk to your HCP if this is a concern for you.

Your HCP may temporarily stop, decrease your dose, or completely stop your treatment with RYBREVANT FASPRO™, RYBREVANT®, or LAZCLUZE® if you have serious side effects.

These are not all of the possible side effects of RYBREVANT FASPRO™, RYBREVANT®, or LAZCLUZE®.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of RYBREVANT FASPRO™, RYBREVANT®, or LAZCLUZE®:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.

You can ask your HCP or pharmacist for information about RYBREVANT FASPRO™, RYBREVANT®, or LAZCLUZE® that is written for health professionals. Do not use LAZCLUZE® for a condition for which it was not prescribed. Do not give LAZCLUZE® to other people, even if they have the same symptoms that you have. It may harm them.

Please read full Prescribing Information for RYBREVANT FASPRO™, RYBREVANT®, and LAZCLUZE®.

cp-493867v1